Work

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Year: 2016

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-16-0308

Authors: Anthony W. Tolcher, Johanna C. Bendell, Kyriakos P. Papadopoulos, Howard A. Burris, Amita Patnaik, Wayne J. Fairbrother, Harvey Wong, Nageshwar Budha, Walter C. Darbonne, Franklin Peale, Michael Mamounas, Stephanie Royer-Joo, Ron Yu, Chia C. Portera, Jeffrey R. Infante

Institutions: South Texas Accelerated Research Therapeutics, Sarah Cannon, Genentech

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Genentech

Award: G1770078678

OpenAlex ID: W2336266139

FWCI: 0.896

Cites: 8

Cited by: 33

Related to: 10